A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

Clinical trial NCT01289223 · TERMINATED

Trial details

NCT number: NCT01289223
Sponsor: Mundipharma Research Limited
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Indolent B-cell NHL

Start date: 2011-02-01
Primary completion: 2018-07-31
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.